STEM has entered into an agreement to sell 7M shares of its common stock to Seaside 88, LP (“Seaside”), a private investment partnership, at a price of $0.865 per share, which represents a 12.6% discount to the closing price per share of 6/29/10. Read more…
We all make mistakes and I am the first to admit! Referencing blog, 6/29/10: Read more…
NBS’ owned Suzhou Erye pharmaceutical subsidiary passed the government inspection by the State Food and Drug Administration (SFDA) in China Read more…
Tarix Pharmaceuticals today announced that its drug, TXA127, has been granted Orphan Drug designation from the FDA as a treatment to enhance engraftment in patients receiving a stem cell transplant. TXA127 has also received Orphan Drug designation for the treatment of Myelodysplastic Syndrome (MDS). Read more…
RENE.L’s loss widened to FY10 (3/31/10) £5.85 M from £ 3.67 M in the prior year. On a per share basis, net loss was 1.8 pence, compared to a loss of 2.4 pence in the previous year. Loss before income taxes widened to £6.22 M, from £4.67M in the previous year. Revenues were GBP 31K, down from £ 93K in the prior year. Read more…
The US Court of Appeals for the District of Columbia ruled (6/27/10) that doctors performing adult stem cell research have ‘competitive standing’ to sue. The court therefore reinstated a federal lawsuit seeking to prohibit and overturn controversial guidelines for public funding of embryonic stem cell research. Read more…
The study is funded through a $10.2M grant from the Robertson Foundation has the potential to establish protocols for the use of stem cells from cord blood. Read more…
PSTI’s meeting with the Paul Ehrlich Institute (PEI), the German regulatory authority for advanced therapy products (ATP) allows designing 2 Phase IIb clinical trials Read more…
CUR sold $10M of units at $2.80 per unit in a registered-direct offering; Read more…
NBS sold a registered direct offering 2,325,582 units with an aggregate gross offering price of $5M. Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.